All Articles

A Georgia-based innovator is tackling cybersecurity’s silent threat: configuration drift. Here’s why Senteon’s automated approach is turning heads.

Record shareholder returns and massive cash flow paint a rosy picture, but a deeper look at Pan American's Q2 results reveals operational stumbles.

North American Construction Group posts record Q2 revenue on its Australian bet, but integration costs and Canadian headwinds reveal a complex growth story.

AGF Investments is slashing fees on its Elements portfolios, a move that benefits investors but signals intense pressure on active managers from low-cost rivals.

With promising data for its GX-03 cream in an underserved patient group, Turn Therapeutics expands its trial, hires an ex-FDA head, and eyes a new disease.

Once burdened by debt, Battalion Oil's aggressive financial overhaul and laser focus on its Monument Draw asset signal a dramatic corporate resurrection.

Beneath the headline loss, Daily Journal's tech subsidiary is flourishing. How does this dual identity shape its future in a post-Munger world?

A Pasadena firm's Inc. 5000 rank reveals a deeper story: how a client-first, fee-only fiduciary model builds unshakeable trust and sustainable success.

After a rocky Q1, Ellington Credit Company's active strategy in the volatile CLO market paid off, delivering strong returns and a blueprint for resilience.

Marchex's standalone revenue is falling, but its major AI acquisition, Archenia, is already boosting its outlook. Can this strategic pivot deliver lasting value?

BGMS is pivoting from fire safety via a reverse merger with Future NRG. The deal gives NRG shareholders 99% control, creating a new environmental services giant.

While Q2 earnings reflect a tough construction market, Omega Flex's strategic CE Mark for its MediTrac tubing opens a new European front for growth.

Nordique Critical Metals advances its key rare earth project, but faces a crucial test balancing promising economics against significant environmental and community hurdles.

Despite grim Q2 financials, Perma-Fix secures a key role in the massive Hanford cleanup, a multi-billion dollar gamble that could define its future.

Atea's promising Hep C drug offers a shorter, simpler regimen for complex patients, but faces a tough market. Meanwhile, the firm tackles a neglected virus.

With key FDA backing and promising clinical data, Allogene Therapeutics is advancing a vision where complex cell therapies are not just for major medical centers.

With pivotal data due in September, Connect Biopharma's rademikibart could redefine acute asthma and COPD care. Can it navigate this clinical tightrope?

BioCardia secures key regulatory backing in the US and Japan, but the real story may be its pivot to a platform provider for the entire cardiac biologics field.

Liftoff Mobile reported a net loss, but a look past the IPO-related accounting reveals a company firing on all cylinders, with its AI platform driving record revenue.

Starlight's Western Canada fund posted a net loss, but a 102% jump in key cash flow metrics reveals a booming operation fueled by a major acquisition.